CD22-Directed CAR-T for Lymphoma: 92% Response, 85% Complete Remission #Lymphoma

Dr. Matthew Frank from Stanford University presents results from a phase 1 trial of a novel CAR-T cell therapy targeting CD22 in patients with follicular lymphoma, mantle cell lymphoma, and other non-Hodgkin lymphoma subtypes.

THE CHALLENGE:
Current CAR-T cell therapies target CD19 and work well initially. However, many patients relapse because cancer cells lose the CD19 target and become resistant.

THE SOLUTION:
CD22-directed CAR-T cells target a different protein on lymphoma cells, offering an alternative for patients whose disease escapes CD19-targeted therapy.

THE TRIAL:
- Phase 1 (first-in-human) trial
- 26 patients treated
- Seven lymphoma subtypes
- Many patients previously received other CAR-T therapy (high-risk population)

IMPRESSIVE RESULTS:
- 92% overall response rate
- 85% complete remission rate
- Minimal neurotoxicity
- Well-tolerated

WHY IT MATTERS:
For lymphoma patients whose cancer escapes CD19-targeted CAR-T, this CD22-targeted approach offers new hope with excellent response rates.

ENROLLMENT:
Trial still enrolling. Patients interested can reach out to Stanford.

Learn more: https://linktr.ee/HealthTreeUniversity

TIMESTAMPS:
0:00 Introduction
0:11 What is CAR-T Cell Therapy?
0:27 Current CD19 CAR-T Therapies
0:48 The Resistance Problem & CD22 Alternative
1:03 Phase 1 Trial Overview & Results
1:26 Response & Remission Rates
1:50 Enrollment & Next Steps

#CAR-T #Lymphoma #CD22 #ClinicalTrial #NewTreatment